Our vision

Affinity is not efficacy.

One is what you measure at the interface. The other is what the patient gets.

We optimize objectives, not interfaces. Therapeutic, enzyme, and metabolic programs are selected on the disease response and the toxicity, carried through the biological context that connects them.

The thesis

The field optimizes the wrong objective.

Binder design works. A target comes in, a molecule is designed to engage it, and the interface is scored. It is a well-posed problem with real progress behind it.

It is also a narrow one. The interface is one aspect of how a designed object behaves. The disease response, the toxicity, the competing interactions, and the metabolic cost all live outside it.

The canonical isoform of every human protein is known. Protein and ligand relationships can be predicted at proteome scale. Genome-scale models of human metabolism are published and open. If a disease outcome is the goal, that context belongs inside the design problem.

Engaging a target is assumed to produce the outcome. Optimize the outcome directly and the assumption goes away.

The objective

Terms that stand for consequences.

A systems model is only useful if you can ask it for something. We write what we care about as terms in the optimization, so a candidate is scored on the state it leaves the system in.

Efficacy

An abstract representation of the disease response: whether engagement moves the system toward the state you were trying to reach.

Abstracted from predicted interaction networks and pathway context.

Toxicity

Predicted liability resolved by tissue and compartment. Where a molecule is active matters as much as how much.

Abstracted from localization annotation, predicted target breadth, and liability proxies.

Interaction burden

The competing relationships a candidate adds to a system already carrying many, drug-drug interaction included. Part of the objective, not a downstream surprise.

Abstracted from protein-ligand screens and published genome-scale metabolic models.

Optimize toward efficacy. Optimize away from toxicity. Score the candidate on the state of the system, not the quality of one contact.

Company trajectory

From useful software to owned biological assets.

Operating products support researchers now. Protein therapeutics are the current capital focus. Partner programs and owned assets extend the same standard.

01
Operating now
SaaS + API
Commercial research products for protein interaction, ligand, annotation, and proteome-scale analysis.

02
Current financing focus
Next-generation protein therapeutics
The first therapeutic asset, and the experimental milestone for the next financing stage.
03
Expansion
Pharma + biosecurity programs
Partner programs spanning therapeutic design and biological resilience.
04
Long horizon
Owned biological assets
Therapeutics, enzymes, and metabolic interventions that Synthyra can develop or partner across health and industrial biology.

Beyond therapeutics

A concentration is an outcome too.

Nothing in the objective is specific to medicine. Swap the disease response for the concentration of a molecule you want more of, keep the toxicity terms, and the same machinery runs metabolic engineering.

Carbon fixation is the clearest case. Rubisco is the enzyme everyone names, and it is slow. But an organism is a network, and a faster Rubisco moves the bottleneck rather than removing it: substrate regeneration, reducing power, competing oxygenation and downstream carbon allocation all shift with it.

Naming the enzyme is a prior. Naming the concentration is an objective.

The whole cycle, not one enzyme

Every protein in the Calvin-Benson-Bassham cycle is a design variable at once, scored on what the pathway produces rather than on any single catalytic rate.

Named products

Sugars and sugar intermediates, glycolic acid, and precursors to fuels and materials are all concentrations a model can be asked to raise.

The same liability terms

Byproduct toxicity and host burden stay in the objective. A pathway that makes more of something and kills the organism has not been improved.

What that reaches is crop yield, nutritional content, and carbon captured into something worth keeping.

The next milestone is experimental.

We are looking for therapeutic-development, experimental, and strategic partners.

Explore the platform